These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA; N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543 [TBL] [Abstract][Full Text] [Related]
7. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823 [TBL] [Abstract][Full Text] [Related]
8. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E; N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408 [TBL] [Abstract][Full Text] [Related]
9. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191 [TBL] [Abstract][Full Text] [Related]
10. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ; Front Neurol; 2021; 12():705407. PubMed ID: 34659081 [No Abstract] [Full Text] [Related]
11. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. Hutchison RM; Evans KC; Fox T; Yang M; Barakos J; Bedell BJ; Cedarbaum JM; Brys M; Siderowf A; Lang AE BMC Neurol; 2021 Nov; 21(1):459. PubMed ID: 34814867 [TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901 [TBL] [Abstract][Full Text] [Related]
13. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
14. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108 [TBL] [Abstract][Full Text] [Related]
15. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C; Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606 [TBL] [Abstract][Full Text] [Related]
17. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315 [TBL] [Abstract][Full Text] [Related]
18. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D; Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448 [TBL] [Abstract][Full Text] [Related]
20. Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease. Oertel WH; Müller HH; Unger MM; Schade-Brittinger C; Balthasar K; Articus K; Brinkman M; Venuto CS; Tracik F; Eberling J; Eggert KM; Kamp C; Kieburtz K; Boyd JT NEJM Evid; 2023 Sep; 2(9):EVIDoa2200311. PubMed ID: 38320207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]